Neurocrine Biosciences Reports Mixed Q4
Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnings per share (EPS) beat estimates significantly.
Overall, the quarter showcased strong performance, particularly from the flagship prescription medication Ingrezza, underscoring the effectiveness of its strategic initiatives.
Source: Neurocrine Biosciences. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. SG = Selling, general, and administrative expenses
Source Fool.com
Neurocrine Bioscience Aktie
120,55 €
-4,78 %
Absolute Beliebtheit: Neurocrine Bioscience hat nur Buy-Einschätzungen.
Ein Kursziel von 149 € für Neurocrine Bioscience könnte zu einer Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 120.55 € führen.
